Psoriasis associated with an increased risk of COVID-19 in real-world study
April 28, 2021
Those treated with TNF-alpha inhibitors, methotrexate, and apremilast had statistically lower risks of COVID-19 vs. those on topical therapy.
COVID-19 vaccines: Safe for immunocompromised patients?
December 17, 2020
Data are limited thus far, and the safety and efficacy of the COVID-19 vaccines in immunocompromised patients remain unknown.
Biologics may protect psoriasis patients against severe COVID-19
November 2, 2020
Preliminary evidence suggests biologics prevent the fearsome COVID-19 late cytokine storm.
COVID-19 outcomes no worse in patients on TNF inhibitors or methotrexate
September 16, 2020
No increase was seen in hospitalization and death rates, providing additional support for keeping patients on these immunosuppressive treatments during the COVID-19 pandemic, although more research is needed and shared decision making is warranted.
Case series suggests biologics, JAK inhibitors safe during pandemic
May 1, 2020
Investigators saw no increase in hospitalizations versus the general population in New York City.
Latest data on COVID-19 patients with rheumatic diseases revealed in registry
April 23, 2020
Data for a total of 583 COVID-19 patients have now been made available.
‘We’re in great distress here,’ infusion center CMO says
April 10, 2020
Thrivewell is also deploying a mobile infusion unit to recovered COVID-19 patients who require an infusion for their autoimmune disease.
Perioperative infliximab does not increase serious infection risk
February 6, 2017
The timing of a last dose of infliximab prior to elective knee or hip replacement surgery does not appear to affect the 30-day risk of serious infection after surgery.